Serologic rebounds after one-year-long treatment for congenital toxoplasmosis.
Djurkovic-Djakovic
O
O
Toxoplasmosis Research Laboratory, Institute for Medical Research, Belgrade, Yugoslavia.
Romand
S
S
Nobrè
R
R
Couvreur
J
J
Thulliez
P
P
D000913:Antibodies, Protozoan / Q000097:blood*; D000981:Antiprotozoal Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007231:Infant, Newborn; D008297:Male; D011247:Pregnancy; D011379:Prognosis; D011739:Pyrimethamine / Q000008:administration & dosage*; D012189:Retrospective Studies; D012698:Serologic Tests; D013411:Sulfadiazine / Q000008:administration & dosage*; D014125:Toxoplasmosis, Congenital / Q000175:diagnosis* / Q000188:drug therapy*
D000913:Antibodies, Protozoan; D000981:Antiprotozoal Agents; D007070:Immunoglobulin A; D007075:Immunoglobulin M; D013411:Sulfadiazine; D011739:Pyrimethamine